EC Number   |
Application |
Reference |
|---|
   3.4.21.69 | diagnostics |
endogenous protein C levels positively correlate with a positive outcome in patients with severe sepsis |
752736 |
| 3.4.21.69 | drug development |
at therapeutically relevant concentrations, activated protein C suppresses the release of interleukin-6 from stimulated human neutrophils and inhibited chemotaxis, without affecting the respiratory burst, apoptosis, and expression of other key cytokines. These effects are likely to be cell-type specific but may have implications for treatment of patients with activated protein C |
697016 |
| 3.4.21.69 | medicine |
a low level of APC-protein C inhibitor complex in plasma may be associated with an increased risk of arteriovenous fistula/graft failure in hemodialysis patients |
700409 |
| 3.4.21.69 | medicine |
activated protein C is a natural protein with anticoagulant and immunomodulatory effects, and its recombinant version is approved by the U.S. Food and Drug Administration to treat severe sepsis |
717942 |
| 3.4.21.69 | medicine |
activated protein C might be useful as therapeutic agent in sepsis, clinical trials, overview |
683548 |
| 3.4.21.69 | medicine |
activated protein C-protein C inhibitor complex correlates with abdominal aortic aneurysm diameter, body mass index, and age. Activated protein C-C-protein C inhibitor complex does not correlate with abdominal aortic aneurysm growth rate. Effect of the abdominal aortic aneurysm diameter on the protein C inhibitor complex concentration differs between men and women |
701370 |
| 3.4.21.69 | medicine |
enzyme mutant 3K3A-APC appears to be safe in ischemic stroke patients and reduced bleeding in the brain after tissue plasminogen activator therapy in a recent phase 2 clinical trial. Studies using human fetal neural stem and progenitor cells show that 3K3A-APC promotes neurogenesis in vitro as well as in vivo in the murine middle cerebral artery occlusion stroke model. 3K3A-APC appears to be safe in ischemic stroke patients and reduced bleeding in the brain after tissue plasminogen activator therapy in a recent phase 2 clinical trial. Enzyme mutant 3K3A-APC may potentially be used for late treatment of stroke in patients in ongoing phase 1 (NCT01151124) and phase 2 (NCT02117635) clinical trials that involve directly injecting manufactured NSCs into the brain of patients that remain moderately to severely disabled following an ischemic stroke |
753070 |
| 3.4.21.69 | medicine |
important role for the aPC/endothelial protein C receptor pathway in reducing metastasis via inhibition of tumor cell adhesion and transmigration |
696947 |
| 3.4.21.69 | medicine |
leukocyte integrins are cellular receptors for recombinant activated protein C and the interaction decreases neutrophil recruitment into tissues, providing a potential mechanism by which recombinant human APC may protect against sepsis |
696948 |
| 3.4.21.69 | medicine |
low molecular weight activated protein C inhibitors might be useful as potential treatment for hemophilic disorders |
683754 |
